Eli Lilly Warns of Dangerous Impurity in Compounded Tirzepatide-B12 Combinations
Key Insights
Eli Lilly has discovered significant levels of an impurity in compounded tirzepatide mixed with vitamin B12, a popular combination offered by telehealth companies and medical spas.
The impurity results from a chemical reaction between tirzepatide and B12, with unknown short- and long-term effects that could limit efficacy or introduce toxicity and immune reactions.
Lilly has notified the FDA about these findings and is calling for regulatory action against mass-compounding of tirzepatide with untested additives.
Eli Lilly has issued a public warning about dangerous impurities found in compounded versions of its blockbuster diabetes and weight loss drug tirzepatide when combined with vitamin B12. The pharmaceutical giant conducted analytical tests on compounded tirzepatide-B12 combinations, a popular formulation offered by telehealth companies, pharmacies, and medical spas, revealing concerning safety risks.
Chemical Reaction Creates Unknown Impurity
Lilly's testing uncovered significant levels of an impurity created as a direct result of a chemical reaction between tirzepatide and vitamin B12. The company emphasized that "nothing is known" about the short- or long-term effects of this interaction in humans, raising serious safety concerns for patients using these compounded products.
The potential risks extend beyond simple efficacy concerns. According to Lilly, the impurity could not only limit the drug's effectiveness but also introduce toxicity and immune reactions. This finding is particularly troubling given that the administration of tirzepatide with B12 is not regulated by the US Food and Drug Administration (FDA).
Public Safety Warning Issued
In an open letter to the public, Lilly stated: "People receiving tirzepatide-B12 products from compounders, telehealth companies, medspas, or anyone else should be aware that they may be using a potentially dangerous product with unknown risks."
The warning comes as tirzepatide, approved in the US under the brand names Mounjaro for type 2 diabetes (search) and Zepbound for weight loss, has become a major revenue driver for Lilly. The company's tirzepatide brands generated $36.5 billion in global sales in 2025, underscoring the widespread use of these medications.
Regulatory Response and Market Dynamics
Lilly has notified the FDA about its findings, adding to the agency's ongoing efforts to crack down on mass-marketing of unapproved drugs. The FDA has already placed increased scrutiny on companies that take advantage of regulatory loopholes to mass-market compounded products to patients.
A duality has emerged in the obesity (search) market in recent years, with some patients choosing branded products while others opt for cheaper compounded versions. Both Lilly and Novo Nordisk have launched numerous legal notices against players in the compounded sector while urging US agencies to strengthen enforcement against mass-compounding practices.
Industry-Wide Enforcement Efforts
The FDA intensified its enforcement activities following telehealth company Hims & Hers (search)' announcement that it would launch a compounded version of Novo's Wegovy (semaglutide) pill. Although a legal dispute between Novo and Hims was recently resolved through a partnership, the FDA continues its regulatory clampdown on companies mass-marketing copycat drugs.
Despite welcoming the FDA's actions, Lilly expressed concern that entities continue to mass-compound tirzepatide. The company stated: "The continued widespread distribution of untested compounded drugs is an unacceptable risk for patients. The FDA's recent actions are an important step to enforce the law and protect patients, and we urgently call on other regulators and law enforcement to do the same."
Call for Comprehensive Action
Lilly is pushing for more aggressive regulatory intervention, specifically urging the FDA to "continue taking action against unlawful mass compounding of tirzepatide that puts the American public at risk, including by requesting a recall of all compounded tirzepatide combined with untested additives like B12."
The discovery highlights the broader safety concerns surrounding the unregulated compounding market, where custom-made medications containing the same active ingredients as marketed drugs are produced without the same rigorous testing and quality controls required for FDA-approved products.